Navigation Links
Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL)

BARCELONA, Spain--(BUSINESS WIRE)--Apr 11, 2007 - New data supporting the clinical development of telaprevir (VX-950), one of the most advanced investigational oral protease inhibitors for the treatment of hepatitis C virus (HCV) infection, will be presented at the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL) in Barcelona this week. In total, nine abstracts related to telaprevir have been accepted for presentation at the EASL conference, including an abstract that describes telaprevir activity against genotypes 2, 3 and 4 in vitro. A late-breaker oral presentation will take place on Saturday, April 14 at 5:45 p.m. Central European Summer Time (11:45 a.m. Eastern Daylight Time). Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) is developing telaprevir in collaboration with Tibotec.

"Hepatitis C is a major global health problem with a significant unmet medical need. Despite treatment advancements in the last 10 years, there is an urgent need for new therapeutic options that can offer patients shorter course therapy and better efficacy," said John Alam, M.D., Executive Vice President, Medicines Development, and Chief Medical Officer of Vertex. "The data to be presented at EASL demonstrate the recent progress made in our clinical evaluation and understanding of telaprevir as a novel treatment for hepatitis C, underscoring our commitment to evaluate telaprevir's potential in important sub-populations, such as those with genotype non-1 hepatitis C."

Telaprevir is one of the most advanced specifically targeted antiviral therapies for HCV (STAT-C). STAT-Cs represent a new approach to hepatitis C treatment by directly targeting the enzymes the virus uses to replicate.

Oral Presentation: Telaprevir Demonstrates Potency Against Genotype 2, 3 and 4 in vitro

Chao Lin, Ph.D., of Vertex, will present an abstract titled, "Telaprevir (VX-950) is a Potent Inhibitor of H
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:8/28/2014)... Aug. 28, 2014 Amgen (NASDAQ: ... License Application (BLA) to the U.S. Food and Drug ... of high cholesterol. Evolocumab is an investigational fully human ... (PCSK9), a protein that reduces the liver,s ability to ... the blood. 1 ­ ...
(Date:8/28/2014)... -- Rx Safes, Inc., the manufacturer of fingerprint recognition home ... new war on drugs to reduce prescription drug abuse, ... than 2,500 children a day experiment with prescription drugs ... accessed from unsecured medicine cabinets, closets and drawers.  While law ... Safes will address the new age drug dealer in ...
(Date:8/28/2014)... 28. August 2014 Sequent ... der Patientenrekrutierung für eine IDE-Pivot-Studie („IDE" ... Beurteilung der Sicherheit und Wirksamkeit des ... („WEB") bekanntgegeben. Adam Arthur, MD, Dozent an ... Neurosurgery/Semmes-Murphey Clinic, und Hauptprüfarzt der WEB-IT-Studie, ...
Breaking Medicine Technology:Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 2Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 3Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 4Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 6Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 7Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 8Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 9Rx Safes, Inc. Announces New War On Drugs 2Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 2Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 3
... ROG; OTCQX: RHHBY) announced plans today to expand its coagulation ... outpatient clinics with the development of a full line of ... is expected to be introduced in the U.S. and Canada ... Roche Diagnostics is the global market leader in ...
... ORLANDO, Fla., Oct. 4, 2011 The benefits of a ... Now, new research has emerged relating to the role gender ... Gender Differences in a Naturalistic Observational Study of Sleep ... the annual Obesity Society meeting in Orlando, Florida this week. ...
Cached Medicine Technology:Roche to Expand Coagulation Testing Portfolio, Develop New Systems for Diagnostic Laboratories in US and Canada by 2014 2Research Presented at The Obesity Society Meeting Shows Link Between BMI and Sleep Patterns 2Research Presented at The Obesity Society Meeting Shows Link Between BMI and Sleep Patterns 3
(Date:8/28/2014)... glue directly on the nerve stumps, but this method ... glue to easily invade the nerve ends. Ordinarily, nerve ... the nerve ends into the conduit because the nerve ... and co-workers from the General Hospital of Chinese PLA ... defined the best parameters for its use through in ...
(Date:8/28/2014)... can be treated with nasal septum cells. Researchers at ... that cells taken from the nasal septum are able ... and can thus repair articular cartilage defects. The nasal ... joint environment is associated with the expression of so-called ... has published the research results together with the ...
(Date:8/28/2014)... One in every 200 Ontarians has been diagnosed with ... living with the disease increasing by 64 per cent ... researchers at the Institute for Clinical Evaluative Sciences (ICES), ... Ottawa Hospital Research Institute. That puts Ontario in the ... The study, published this week in Inflammatory Bowel ...
(Date:8/28/2014)... rheumatoid arthritis patients in the study who were on ... not take them as prescribed in the first six ... from 60 hospitals around the UK involved in the ... for Genetics and Genomics at The University of Manchester, ... the drugs correctly, known as ,non-adherence, reduced their effectiveness ...
(Date:8/28/2014)... 28, 2014 BCC Research ( http://www.bccresearch.com ... SYSTEMS: TECHNOLOGIES AND GLOBAL MARKETS , the global market ... in 2013. Driven by the need for replacement of ... in emerging geographies, the market is expected to grow ... (CAGR) of 8.5% from 2013 through 2018. , While ...
Breaking Medicine News(10 mins):Health News:From nose to knee: Engineered cartilage regenerates joints 2Health News:Ontario has one of the highest rates of IBD in the world 2Health News:Arthritis patients failing to take expensive medication, according to new research 2Health News:Global Market for Surgical Navigation Systems Expected to Reach $631.9 Million in 2018; ENT Systems Segment Leading With 10.4% CAGR 2Health News:Global Market for Surgical Navigation Systems Expected to Reach $631.9 Million in 2018; ENT Systems Segment Leading With 10.4% CAGR 3
... NEW YORK (Nov. 22 2009) -- Physician-scientists from Weill Cornell ... to be a powerful target for the treatment of non-Hodgkin,s ... blood cells. By exploiting this mechanism, researchers have been able ... animal models. Promising results have led to the design ...
... ... can be both fun and joyous. It can also be stressful and tiring ... foods -- factors that can, over time, increase your risk of cancer. That,s ... 10 Food Tips that can help ensure a happier, more healthful holiday season, ...
... , WASHINGTON, Nov. 21 DNC Chairman ... to begin full debate of health insurance reform legislation. ... Senate took another historic step on the road to enacting ... will now have an opportunity to debate the health reform ...
... , , Association Discusses Key ... Reform , ST. CHARLES, Ill., Nov. 21 ... Affordable Health Care for America Act (H.R. 3962), and the ... decisive steps to fix our nation,s broken health care system. ...
... , ... addictive game, SplitWords, is now available on the iPhone and iPod Touch. , ... Mountain View, CA (PRWEB) November 21, 2009 ... iPod Touch. Split Words is designed to help banish that ,tip of the tongue, syndrome ...
... , Pioneering Neurologist Closer to Understanding ... Dr. Jeremy Schmahmann, Professor of Neurology at Harvard Medical ... Boston, on Thursday, November 19, presented his laboratory,s research ... the launch of the MINDlink Foundation. , Dr. Schmahmann ...
Cached Medicine News:Health News:New cancer target for non-Hodgkin's lymphoma 2Health News:Top 10 Food Tips for the Holidays from the National Foundation for Cancer Research 2Health News:Top 10 Food Tips for the Holidays from the National Foundation for Cancer Research 3Health News:Democratic National Committee Chairman Tim Kaine's Statement on the Senate's Vote to Proceed to Full Floor Debate of Health Insurance Reform Legislation 2Health News:AARP Hosts Rep. Bill Foster In Health Care Reform Forum 2Health News:HAPPYneuron releases iPhone Brain Game 2Health News:HAPPYneuron releases iPhone Brain Game 3Health News:MINDlink Foundation Launches to Connect the Cerebellum to Cures 2
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
Medicine Products: